Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
Jh3dvGhV7dKdpXZf
